Skip to main content
SpringerLink
Log in

Translational Strategies for the Development of a Wound Healing Technology (Idea) from Bench to Bedside

  • Protocol
  • First Online:
Wound Regeneration and Repair

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1037))

Abstract

This chapter will outline strategies and ideas for the commercialization a promising wound healing technology discovered in an academic setting. This would include, but not limited to addressing topics such as intellectual property protection, funding, technology development, and regulatory aspects (i.e., navigating through the FDA).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ghatnekar GS, O’Quinn MP, Jourdan LJ, Gurjarpadhye AA, Draughn RL, et al (2009) Connexin43 carboxyl-terminal peptides reduce scar progenitor and promote regenerative healing following skin wounding. Regenerative Medicine. 4:205–223

    Google Scholar 

  2. Gourdie RG et al (2006) The unstoppable connexin43 carboxyl-terminus: new roles in gap junction organization and wound healing. Ann N Y Acad Sci 1080:49–62

    Article  CAS  PubMed  Google Scholar 

  3. Rhett JM et al (2008) Novel therapies for scar reduction and regenerative healing of skin wounds. Trends Biotechnol 26(4):173–180

    Article  CAS  PubMed  Google Scholar 

  4. Ghatnekar G et al (2009) Connexin43 carboxyl-terminal peptides reduce scar progenitor and promote regenerative healing following skin wounding. Regen Med 4:205–223

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Gautam G, Abhijit G, Spencer R, Platatinus J, Gourdie R. (2008). Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds. The 2013 ASCI/AAP Joint Meeting, April 26-28, Chicago, IL. Abstract 190

    Google Scholar 

  6. Woolf SH (2008) The meaning of translational research and why it matters. JAMA 299(2):211–213

    CAS  PubMed  Google Scholar 

  7. Sung NS, Crowley WF Jr, Genel M, et al (2003) Central challenges facing the national clinical research enterprise. JAMA 289(10):1278–1287

    Google Scholar 

  8. Conway B (2010) Bridging the biotechnology financing divide. Wall Street BioBeat Dec 1, 2010 (Vol 30, No 21)

    Google Scholar 

  9. Pienta KJ (2010) Successfully accelerating translational research at an Academic Medical Center: the University of Michigan-Coulter Translational Research Partnership Program. Clin Trans Sci 3:316–318. doi:10.1111/j.1752 8062.2010.00248.x

    Article  Google Scholar 

  10. Abrams I et al (2009) How are U.S. technology transfer offices tasked and motivated—is it all about the money? Res Manag Rev 17:1

    Google Scholar 

  11. Sandelin JC (2007) Dealing with spinout companies. In: Krattiger A, Mahoney RT, Nelsen L et al (eds) Intellectual property management in health and agricultural innovation: a handbook of best practices. MIHR, Oxford, UK. Available online at www.ipHandbook.org

  12. Mullen P (2007) Where VC fears to tread. Biotechnol Healthc 4(5):29–35

    PubMed Central  PubMed  Google Scholar 

  13. Aldag J, Kessel M, Ibrahim A, Hill R, McCubbin P (2008) Other ways of financing your company. Nat Biotechnol 26(2):1–3

    Google Scholar 

  14. Burns LR et al (2009) Market entry and exit by biotech and device companies funded by Venture Capital. Health Aff 28(1):w76–w86

    Article  Google Scholar 

  15. Lazonick W, Tulum Ö (2010) US biopharmaceutical finance and the sustainability of the biotech boom. Industry Studies Working Paper: 2010-01

    Google Scholar 

  16. Sapien J. How San Diego researchers walk through the ‘Valley of Death’. http://www.voiceofsandiego.org/articles/2008/04/09/news/01valleydeath040808.txt. Accessed 1 Nov 2011

  17. Philippidis A (2011) More VC but fewer deals signal that investors are becoming even more risk averse. Analysis & insight. Genetic Engineering & Biotechnology News May 5, 2011

    Google Scholar 

  18. Tirrell M. Research funding grows scarcer for early-stage biotech companies. http://www.bloomberg.com/news/2011-06-14/research-funding-grows-scarcer-for-early-stage-biotech-companies.html?cmpid=yhoo. Accessed Nov 2011

  19. SF Public Press (2011) Biotechnology startups struggle as venture capitalists seek quick hits. http://sfpublicpress.org/news-notes/2011-05/biotechnology-startups-struggle-as-venture-capitalists-seek-quick-hits

  20. Spack E (2005) Minding the drug development gap. The Scientist (Vol 19, No 21)

    Google Scholar 

  21. Beyond borders: global biotechnology report (2011) http://www.ey.com/GL/en/Industries/Life-Sciences/Beyond-borders--global-biotechnology-report-2011

  22. Kaufman R. Bridging the early stage funding gap. http://www.techjournalsouth.com/2007/05/bridging-the-early-stage-funding-gap/. Accessed Nov 2011

  23. Wessner CW (2009) Venture funding and the NIH SBIR Program. Committee for capitalizing on science, technology, and innovation: an assessment of the small business innovation research program. In: Wessner CW (ed). National Research Council. The National Academies Press, Washington, DC

    Google Scholar 

  24. SBIR. http://www.sbir.gov/about/about-sbir. Accessed Nov 2011

  25. STTR. http://www.sbir.gov/about/about-sttr. Accessed Nov 2011

  26. Technology Alliance. Investing in our competitive future: approaches to increase early stage capital in Washington State. A report of the technology alliance seed funding committee, January 2007. www.technology-alliance.com

  27. Takahashi D. Angels invested $20.1B in 2010—but they’re taking fewer risks. http://venturebeat.com/2011/04/12/angels-invested-20-1b-in-2010-but-theyre-taking-fewer-risks/. Accessed Nov 2011

  28. Jeffrey Sohl (2011) The Angel Investor market in 2010: a market on the rebound. Center for Venture Research, April 12, 2011. http://wsbe.unh.edu/cvr

  29. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22:151–185

    Article  PubMed  Google Scholar 

  30. DiMasi JA, Grabowski HG (2007) The cost of biopharmaceutical R&D: is biotech different? Manage Decis Econ 28:469–479

    Article  Google Scholar 

  31. Roth D, Cuatrecasas P (2010) The distributed partnering model for drug discovery and development. Ewing Marion Kauffman Foundation, January 2010. http://www.kauffman.org/uploadedFiles/distributed-partnership-model_12510.pdf. Accessed Nov 2011

  32. Gulbranson CA, Audretsch DB (2008) Proof of concept centers: accelerating the commercialization of University innovation. Ewing Marion Kauffman Foundation, January 2008. http://www.kauffman.org/uploadedFiles/POC_Centers_01242008.pdf. Accessed Nov 2011

Download references

Author information

Authors and Affiliations

  1. FirstString Research, Inc., Mount Pleasant, SC, USA

    Gautam S. Ghatnekar & Tuan A. Elstrom

  2. Halimed Pharmaceuticals, Charleston, SC, USA

    Gautam S. Ghatnekar

  3. Regranion, LLC, Charleston, SC, USA

    Gautam S. Ghatnekar & Tuan A. Elstrom

Authors
  1. Gautam S. Ghatnekar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tuan A. Elstrom
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Virginia Tech Carilion Research Institut, Roanoke, Virginia, USA

    Robert G. Gourdie

  2. School of Pharmacy, MCPHS University, Worcester, Massachusetts, USA

    Tereance A. Myers

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this protocol

Cite this protocol

Ghatnekar, G.S., Elstrom, T.A. (2013). Translational Strategies for the Development of a Wound Healing Technology (Idea) from Bench to Bedside. In: Gourdie, R., Myers, T. (eds) Wound Regeneration and Repair. Methods in Molecular Biology, vol 1037. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-505-7_33

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-505-7_33

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-504-0

  • Online ISBN: 978-1-62703-505-7

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation